HSK39004

HSK39004 is a novel small molecule drug developed by Haisco Pharmaceutical Group for the treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and pulmonary emphysema. It acts as a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4), enzymes involved in the regulation of inflammatory responses and airway smooth muscle tone. By inhibiting both PDE3 and PDE4, HSK39004 is designed to reduce inflammation and improve airway function in respiratory diseases. The drug is being developed primarily as an inhalation powder formulation, with clinical trials currently in Phase 1 to evaluate its safety, tolerability, and pharmacokinetics[1][2][3][4][5][7].